... A web-based Atlas of Patient-Derived Xenografts of cancer patients:A resource of MURAL PDX data
Download csv Download xlsx
PDX ID Sample Site Sample Source Age Sample Collected PSA at diagnosis (ng/mL) Id Sample ID Current PDX Generation Average PDX Generation Time (days ± SEM) Tumor preparation2 Pubmed ID Created Date Audit Date Patient Id Gleason Score Primary Gleason Score Secondary Gleason Score Grade Group Tumour Grade D'Amico Risk Classification Primary Tumour Volume (cc) Treatment Prior to Specimen Collection PDX Host Type PDX Graft Site
463.58A Tumour adjacent to pancreas Autopsy 57 7.8 62 463.58A 7 67 ± 5 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 455/463 0.0 Radiotherapy, zoladex, docetaxel, enzalutamide, niraparib, cabazitaxel Testosterone supplemented Subcutaneous
472M Left ilium Biopsy 52 630 63 472M 20 54 ± 7 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 472 0.0 ADT, docetaxel Testosterone supplemented Subcutaneous
472M Cx Left ilium Biopsy 52 630 64 472M 10 (5*) 51 ± 3 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 472 0.0 ADT, docetaxel Castrate Subcutaneous
1001R Dura Biopsy 45 5.2 71 1001T 1000 1000 tumor solid 10000 13/05/2024 1:03 a.m. 13/05/2024 1 a.m. 1001 None
1007.R Dura Biopsy 45 5.3 72 1007T 1000 1000 tumor solid 10000 13/05/2024 1:03 a.m. 13/05/2024 1 a.m. 1007 None
1010.R 5.2 261 1010T G5 1000 tumor solid 15/11/2024 3:18 p.m. 15/11/2024 3:18 p.m. 1010
test Dura Biopsy 45 5.3 262 1007T 11 1 1 15/11/2024 4:18 p.m. 15/11/2024 4:18 p.m. 1007 None